MEFAS- Hybrid salt of artesunate and mefloquine to treat Malaria

Project 60

Problem to be solved:
• Disease of worldwide range and endemic in Brazil
• High morbidity and mortality
• Parasite resistance to current medicine

Proposed Innovation:
• Hybrid salt with two active principals: artesunate and mefloquin (mefas)
• Low toxicity

Differential:
• Treatment with lower dose of mefloquina
• Superior efficacy in treating malaria
• Lower toxicity compared to current medicine when used alone or in combination
• New drugs to control the disease
• Lower cost

Development status:
Scale-up

Intellectual property Status:
BRPI0401107-4 (corresponding application filed in China, India, the U.S. and Europe)

Technology transfer status:
Prospecting partnership

Coordinator:
Nubia Boechat Andrade / Farmanguinhos

Contact:
Gestec/VPPIS – Phone: 21 3882-9099 / 3882-9120 or portfolio@fiocruz.br